Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
77 Leser
Artikel bewerten:
(0)

2-Day Workshop by Ex-FDA Official: eCTD Submissions of IND and NDA/BLA to the US FDA, EU and Canada - Orlando, FL, United States - February 1st-2nd, 2018

DUBLIN, November 15, 2017 /PRNewswire/ --

The "eCTD Submissions of IND and NDA/BLA to the US FDA, EU and Canada: 2-Day Workshop by Ex-FDA Official" conference has been added to Research and Markets' offering.

Research and Markets Logo

The international agreement to assemble all Quality, Safety and Efficacy information for a drug or biologic product into a common format (called the CTD - Common Technical Document) has improved the speed and efficiency for companies working in global development programs and clarified expectations by regulatory bodies. Reformatting for multiple submissions is substantially limited. The CTD has improved the regulatory review processes and enabled implementation of good review practices. The eCTD has increased efficiency for reviewers and improved submission times.

This two day workshop will provide you with an in-depth review of the content and format requirements of the CTD/eCTD. Hands-on activities will include organizing specific study reports and other documents into the CTD, using tools for the project management of the CTD preparation, and pre-publishing an eCTD.

Who Should Attend

  • Regulatory Affairs
  • Quality Assurance
  • Pharmacovigilance
  • Project Management
  • Regulatory Operations
  • Medical and Technical writers
  • Professionals preparing IND, DMFs, NDAs and other submissions
  • IT Professionals
  • Anyone responsible for providing content for the CTD

Agenda:

Day 01 (8:30 AM - 4:30 PM)

Lecture 1: Overview of the drug development program and source of relevant submission documents
Lecture 2: Discussion of the roles and responsibilities for CTD preparation
Lecture 3: Review of the CTD format requirements
Lecture 4: Discussion on the successful transition from other formats to the CTD
Lecture 5: Placement of content into the CTD format; including less obvious items
Lecture 6: Review of different requirements across regions (US, EU, Canada)
Lecture 7: Implementing tools for the project management of CTD preparation and publishing

Day 02 (8:30 AM - 4:30 PM)

Lecture 8: Technical requirements for an eCTD submission
Lecture 9: Document naming requirements
Lecture 10: Building the folder structure
Lecture 11: Internal document requirements for the eCTD
Lecture 12: Performing "pre-publishing" work for each document
Lecture 13: Tools for tracking and managing eCTD content
Lecture 14: Performing quality checks on the eCTD
Lecture 15: Updating content in the CTD and eCTD (amendments, supplements, variations, etc.)

For more information about this conference visit https://www.researchandmarkets.com/research/g2lndp/ectd_submissions

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.